Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
Business Of Biotech
00:00
Is It a Party, a Celebration?
Dr. Sanjay Gupta: BI is a company driven by science and its ability to reach patients. He says the data was so strong telling us that we should go in that direction, that convincing the leaders was possible. "We felt that we could do it," he said of going internal rather than spin off or partner it. 'I'm hoping we're right'
Transcript
Play full episode
